Analyst Price Targets — SNY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 11:26 am | Sarita Kapila | Morgan Stanley | $49.00 | $42.98 | TheFly | Sanofi price target lowered to $49 from $52 at Morgan Stanley |
| May 1, 2026 7:34 pm | — | Morgan Stanley | $52.00 | $46.08 | TheFly | Sanofi downgraded to Equal Weight from Overweight at Morgan Stanley |
| April 20, 2026 8:31 am | Peter Verdult | BNP Paribas | $50.00 | $48.06 | TheFly | Sanofi downgraded to Neutral from Outperform at BNP Paribas |
| June 2, 2025 10:07 am | Sarita Kapila | Morgan Stanley | $56.00 | $49.19 | TheFly | Sanofi resumed with an Equal Weight at Morgan Stanley |
| September 10, 2024 5:42 am | Luisa Hector | Berenberg Bank | $64.00 | $58.51 | TheFly | Sanofi price target raised to $64 from $56 at Berenberg |
| July 26, 2024 7:33 am | Jasper Hellweg | Argus Research | $60.00 | $52.54 | StreetInsider | Sanofi-Aventis (SNY) PT Raised to $60 at Argus |
| April 3, 2024 12:55 pm | Jasper Hellweg | Argus Research | $55.00 | $48.00 | StreetInsider | Sanofi-Aventis (SNY) PT Lowered to $55 at Argus, 'BUY as FDA reviews Dupixent for COPD' |
| December 21, 2022 1:30 pm | Iain Simpson | Barclays | $48.07 | $48.17 | TheFly | Sanofi confirms to Bloomberg Zantac settlement in California |
Latest News for SNY
Sanofi (NASDAQ: SNY - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, three have given a buy recommendation and two have assigned a
Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shots should target the dominant XFG variant.
The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside potential ahead for shares of the French pharmaceutical giant.
On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Trump's Gold Standard Childhood Vaccine Recommendations will be temporary. Sanofi is trading at a significant discount, with a non-GAAP P/E ratio [FWD] of 9.2x, 53.2% below the sector median.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SNY.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.